GlassScriptPhysician profile
Michael T Harris
NPI 1952579021
$2,043.50
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $305 · 2021: $395 · 2022: $658 · 2023: $213 · 2024: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $329.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $673.88 | 2021-2024 | |
| Amgen INC. | $170.98 | 2019-2023 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $157.14 | 2019-2023 | Breztri |
| Allergan, INC. | $130.41 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $125.01 | 2023 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $115.74 | 2022 | |
| Lilly USA, LLC | $111.39 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.96 | 2019-2021 | |
| Glaxosmithkline, LLC. | $75.39 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.66 | 2020 | |
| Sunovion Pharmaceuticals INC. | $46.10 | 2019-2020 | |
| Mylan Specialty L.P. | $33.29 | 2020-2021 | |
| Novo Nordisk INC | $28.50 | 2020-2021 | |
| Adlon Therapeutics L.P. | $27.20 | 2020-2021 | |
| Pfizer INC. | $26.52 | 2019-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.47 | 2022 | |
| Axsome Therapeutics, INC. | $24.43 | 2024 | Auvelity |
| Lundbeck LLC | $20.91 | 2024 | Rexulti |
| Daiichi Sankyo INC. | $20.66 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $17.69 | 2019 | |
| Vanda Pharmaceuticals INC. | $16.69 | 2024 | Fanapt |
| Grifols USA, LLC | $16.05 | 2021 | |
| Ironshore Pharmaceuticals INC. | $13.36 | 2019 | |
| Shire North American Group INC | $12.85 | 2019 | |
| Eisai INC. | $12.34 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.